2009   Print Screen
News Releases
    2010
    2009
    2008
- -2007
-- 2006
-- 2005

DOYLESTOWN, PA – December 8, 2009 -- QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, announced today the successful debut of its new flagship point-of-care (POC) diagnostic reader device, Q-Reader™, at MEDICA 2009 on November 18-21, 2009, in Düsseldorf, Germany.

DOYLESTOWN, PA – November 6, 2009 – QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the Company will demonstrate its latest technology at MEDICA 2009, the world's leading medical trade fair, to be held November 18-21, 2009, in Düsseldorf, Germany.  The trade show will be host to a milestone event for QuantRx as the point-of-care (POC) medical device pioneer will introduce for the first time its flagship diagnostic reader device, Q-Reader™.

DOYLESTOWN, PA – July 31, 2009 -- QuantRx Biomedical Corporation (OTCBB: QTXB) announced today the creation of a joint venture with NuRx Pharmaceuticals, Inc. (OTCBB: NUXP) to accelerate efforts to capitalize opportunities in the fast growing market for Point-of-Care (POC) products. 

DOYLESTOWN, PA – June 16, 2009 - QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that its affiliate, FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET

DOYLESTOWN, PA – May 4, 2009 – QuantRx® Biomedical Corporation (OTCBB:QTXB), a diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced that, in conjunction with its strategic partner, ALT BioScience, QuantRx' Senior Scientist, Dr. Tony Burgess-Cassler, presented his work on developing a new method for the rapid detection of oral disease at the 2009 International Association for Dental Research (IADR) Conference in Miami, Florida.

 
 
 
 


                                                                

 

If you are a stockholder and wish to be added to our electronic mailing list, please email us your name and current email address to receive updates and the latest press releases.

DOYLESTOWN, PA –February 10, 2009 -- QuantRx Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the U.S. Patent and Trademark Office has issued a new patent expanding QuantRx’s oral testing intellectual property suite. 

DOYLESTOWN, PA – February 2, 2009 – QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced it has entered into a Technology License Agreement with Church & Dwight Co., Inc. (NYSE:CHD).

DOYLESTOWN, PA – January 27, 2009 – QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, is pleased to announce that QuantRx’s FluoroPharma, Inc. has been issued U.S. Patent No. 7,438,891, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose (FDG), by the United States Patent and Trademark Office.

DOYLESTOWN, PA – January 14, 2009 -- QuantRx Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its RapidSense drugs-of-abuse (DOA) Phencyclidine (PCP) test.

DOYLESTOWN, PA – January 6, 2009 -- QuantRx Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its RapidSense drugs-of-abuse (DOA) Methamphetamine test.


© Copyright 2007 - QuantRx® Biomedical Corporation